672 related articles for article (PubMed ID: 28507029)
21. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2.
Krishnan L; Gurnani K; Dicaire CJ; van Faassen H; Zafer A; Kirschning CJ; Sad S; Sprott GD
J Immunol; 2007 Feb; 178(4):2396-406. PubMed ID: 17277146
[TBL] [Abstract][Full Text] [Related]
22. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
23. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
24. Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.
Karlsson I; Borggren M; Nielsen J; Christensen D; Williams J; Fomsgaard A
Hum Vaccin Immunother; 2017 Aug; 13(8):1823-1830. PubMed ID: 28613978
[TBL] [Abstract][Full Text] [Related]
25. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
26. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
27. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V
Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430
[TBL] [Abstract][Full Text] [Related]
28. DNA is an efficient booster of dendritic cell-based vaccine.
Li J; Valentin A; Beach RK; Alicea C; Felber BK; Pavlakis GN
Hum Vaccin Immunother; 2015; 11(8):1927-35. PubMed ID: 26125100
[TBL] [Abstract][Full Text] [Related]
29. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11.
Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y
Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465
[TBL] [Abstract][Full Text] [Related]
31. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
32. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.
Minigo G; Scholzen A; Tang CK; Hanley JC; Kalkanidis M; Pietersz GA; Apostolopoulos V; Plebanski M
Vaccine; 2007 Jan; 25(7):1316-27. PubMed ID: 17052812
[TBL] [Abstract][Full Text] [Related]
33. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination.
Schreiber TH; Wolf D; Bodero M; Gonzalez L; Podack ER
J Immunol; 2012 Oct; 189(7):3311-8. PubMed ID: 22956587
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
[TBL] [Abstract][Full Text] [Related]
35. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
36. Modulating specific priming of immune effector functions by DNA-based vaccination strategies.
Reimann J; Schirmbeck R
Dev Biol (Basel); 2000; 104():15-24. PubMed ID: 11713813
[TBL] [Abstract][Full Text] [Related]
37. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
38. Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization.
Sudowe S; Dominitzki S; Montermann E; Bros M; Grabbe S; Reske-Kunz AB
Immunology; 2009 Sep; 128(1 Suppl):e193-205. PubMed ID: 18800984
[TBL] [Abstract][Full Text] [Related]
39. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.
Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY
Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404
[TBL] [Abstract][Full Text] [Related]
40. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.
Wiedig CA; Kramer U; Garbom S; Wolf-Watz H; Autenrieth IB
Vaccine; 2005 Oct; 23(42):4984-98. PubMed ID: 15985316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
